# A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

> **NCT00532077** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** rhPTH(1-34)
- **DRUG:** SB-751689 100 mg
- **DRUG:** SB-751689 400 mg

## Key facts

- **NCT ID:** NCT00532077
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532077, "A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00532077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*